astemizole has been researched along with Coronavirus Infections in 1 studies
Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.
astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.
Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, DE | 1 |
| Jang, GM | 1 |
| Bouhaddou, M | 1 |
| Xu, J | 1 |
| Obernier, K | 1 |
| White, KM | 1 |
| O'Meara, MJ | 1 |
| Rezelj, VV | 1 |
| Guo, JZ | 1 |
| Swaney, DL | 1 |
| Tummino, TA | 1 |
| Hüttenhain, R | 1 |
| Kaake, RM | 1 |
| Richards, AL | 1 |
| Tutuncuoglu, B | 1 |
| Foussard, H | 1 |
| Batra, J | 1 |
| Haas, K | 1 |
| Modak, M | 1 |
| Kim, M | 1 |
| Haas, P | 1 |
| Polacco, BJ | 1 |
| Braberg, H | 1 |
| Fabius, JM | 1 |
| Eckhardt, M | 1 |
| Soucheray, M | 1 |
| Bennett, MJ | 1 |
| Cakir, M | 1 |
| McGregor, MJ | 1 |
| Li, Q | 1 |
| Meyer, B | 1 |
| Roesch, F | 1 |
| Vallet, T | 1 |
| Mac Kain, A | 1 |
| Miorin, L | 1 |
| Moreno, E | 1 |
| Naing, ZZC | 1 |
| Zhou, Y | 1 |
| Peng, S | 1 |
| Shi, Y | 1 |
| Zhang, Z | 1 |
| Shen, W | 1 |
| Kirby, IT | 1 |
| Melnyk, JE | 1 |
| Chorba, JS | 1 |
| Lou, K | 1 |
| Dai, SA | 1 |
| Barrio-Hernandez, I | 1 |
| Memon, D | 1 |
| Hernandez-Armenta, C | 1 |
| Lyu, J | 1 |
| Mathy, CJP | 1 |
| Perica, T | 1 |
| Pilla, KB | 1 |
| Ganesan, SJ | 1 |
| Saltzberg, DJ | 1 |
| Rakesh, R | 1 |
| Liu, X | 1 |
| Rosenthal, SB | 1 |
| Calviello, L | 1 |
| Venkataramanan, S | 1 |
| Liboy-Lugo, J | 1 |
| Lin, Y | 1 |
| Huang, XP | 1 |
| Liu, Y | 1 |
| Wankowicz, SA | 1 |
| Bohn, M | 1 |
| Safari, M | 1 |
| Ugur, FS | 1 |
| Koh, C | 1 |
| Savar, NS | 1 |
| Tran, QD | 1 |
| Shengjuler, D | 1 |
| Fletcher, SJ | 1 |
| O'Neal, MC | 1 |
| Cai, Y | 1 |
| Chang, JCJ | 1 |
| Broadhurst, DJ | 1 |
| Klippsten, S | 1 |
| Sharp, PP | 1 |
| Wenzell, NA | 1 |
| Kuzuoglu-Ozturk, D | 1 |
| Wang, HY | 1 |
| Trenker, R | 1 |
| Young, JM | 1 |
| Cavero, DA | 1 |
| Hiatt, J | 1 |
| Roth, TL | 1 |
| Rathore, U | 1 |
| Subramanian, A | 1 |
| Noack, J | 1 |
| Hubert, M | 1 |
| Stroud, RM | 1 |
| Frankel, AD | 1 |
| Rosenberg, OS | 1 |
| Verba, KA | 1 |
| Agard, DA | 1 |
| Ott, M | 1 |
| Emerman, M | 1 |
| Jura, N | 1 |
| von Zastrow, M | 1 |
| Verdin, E | 1 |
| Ashworth, A | 1 |
| Schwartz, O | 1 |
| d'Enfert, C | 1 |
| Mukherjee, S | 1 |
| Jacobson, M | 1 |
| Malik, HS | 1 |
| Fujimori, DG | 1 |
| Ideker, T | 1 |
| Craik, CS | 1 |
| Floor, SN | 1 |
| Fraser, JS | 1 |
| Gross, JD | 1 |
| Sali, A | 1 |
| Roth, BL | 1 |
| Ruggero, D | 1 |
| Taunton, J | 1 |
| Kortemme, T | 1 |
| Beltrao, P | 1 |
| Vignuzzi, M | 1 |
| García-Sastre, A | 1 |
| Shokat, KM | 1 |
| Shoichet, BK | 1 |
| Krogan, NJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883] | Phase 2 | 301 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
1 other study available for astemizole and Coronavirus Infections
| Article | Year |
|---|---|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |